MBX Biosciences closes $115 million financing
With the aim of advancing its pipeline of Precision Endocrine Peptides (PEPs) therapeutic candidates to tread a wide array of endocrine disorders, Indiana, USA-based MBX Biosciences today announced the closing of a Series B financing.
MBX first emerged in 2019, based on technology from Richard DiMarchi, an ex-Eli Lilly (NYSE: LLY) executive and serial entrepreneur. Fellow serial entrepreneur Kent Hawryluk serves as chief executive and has brought the company into Phase I with a lead program and advanced a broader pipeline to date on $35 million from its Series A.
PEPs are based on technology from peptide pioneer Dr DiMarchi (known for contributing to discovery and development of Humalog, Glucagon, Forteo) to have superior properties that overcome key limitations of traditional peptide therapeutics.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze